Akèy › Myelom miltip k ap boukante › Massachusetts
Etid klinik pou Myelom miltip k ap boukante nan Massachusetts
6 etid pou Myelom miltip k ap boukante ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Dana Farber / Harvard Cancer Center, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07393282Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- Tufts Medical Center, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT03937635Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT05469893A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT06140524Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- ak 2 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 7, 2026 · NCT02269592Screening for AL Amyloidosis in Smoldering Multiple Myeloma
- Tufts Medical Center, Boston
Ap rekriteEtid obsèvasyon
Laj 40 ak plis · Tout sèks · Mizajou Aug 6, 2025 · NCT06365060Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.